Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $28.2B | $32.5B | $36.7B | $38.9B | $42.6B | $45.1B | $51.6B | $59.4B | $57.6B | $58.8B | $53.6B | $50.4B | $49.4B | $50.1B | $53.2B | $48.7B | $49.9B | $52.9B | $51.8B | $46.7B |
Discover the top 50 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 50 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 50 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Novartis AG's last 12-month Revenue is $49.3B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novartis AG's Revenue growth was (5.8%). The average annual Revenue growth rates for Novartis AG have been (0.4%) over the past three years, (0.1%) over the past five years.
Over the last year, Novartis AG's Revenue growth was (5.8%), which is lower than industry growth of 0.1%. It indicates that Novartis AG's Revenue growth is Bad.